Catch up on the top radiology content of the past week.
|Articles|August 19, 1998
FDA clears ELGEMS artifact correction
The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by
Advertisement
The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by ELGEMS, which are sold by Elscint as VariCam and by GE Medical Systems as Millennium VG. Elscint plans to begin shipments of VTransACT for VariCam in the first quarter of 1999, according to a spokesperson for the company. ELGEMS also received 510(k) clearance for a set of ultra-high-energy collimators, called VPC-94. The collimators are designed to be used on VariCam for FDG cardiac imaging.
Advertisement
Related to this article
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
In the first of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss current challenges with reimbursement for AI in radiology.
Catch up on the latest imaging research from the recent European Society of Cardiology (ESC) Congress.
The use of adjunctive AI for pulmonary nodule assessment on chest CT exams led to over a three-minute reduction in median reporting time, according to newly reported research.
In the first of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed recently published research showing significant declines in computed tomography (CT) radiation dosing over the past decade.
A new study shows that even small plaque volume may be associated with significantly higher risk for cardiovascular events, making the enhanced spatial resolution available with advanced imaging even more critical in risk stratification.
In comparison to contrast-enhanced CT, FAPI PET was associated with over 27 percent higher sensitivity for peritoneal carcinomatosis in the small bowel and 53 percent higher sensitivity in the upper abdomen, according to a new study involving 200 women with primary ovarian carcinoma.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Brain MRI Study Reveals Higher Brain Age Gap and White Matter Hyperintensity for Those in Disadvantaged Neighborhoods
2
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 2
3
Breast Imaging in Focus: Key Pearls from New Guidelines on Proliferative Breast Lesions with Atypia and LCIS
4
Molecular Imaging in Focus: Can the Newly FDA-Approved PET Agent Floretyrosine F18 Have an Impact for Glioma Imaging?
5